Also known as: gastroesophageal cancers
Studies in gastroesophageal and locally advanced rectal cancers linked dynamic ctDNA monitoring to treatment response and prognosis. MRD clearance, more than 90% ctDNA declines, and early ctDNA clearance were associated with better outcomes.
New ASCO guideline emphasizes biomarker-driven treatment for advanced gastroesophageal cancer, recommending upfront testing for HER2, PD-L1, MSI/MMR, and CLDN18.2 to guide immunotherapy and targeted therapy selection.
NovaBridge Biosciences has enrolled the first patient in a global Phase 2 study evaluating givastomig in combination with nivolumab and chemotherapy for HER2-negative, first-line metastatic gastric cancer, with top-line results expected in 2027.
Insilico Medicine and Memorial Sloan Kettering Cancer Center have entered a collaborative research agreement to discover new therapeutic targets for gastroesophageal malignancies using AI-powered platforms and extensive multi-omic clinical datasets.
Antibody-drug conjugates targeting TROP2 with topoisomerase I inhibitor payloads are currently marketed in breast and lung cancer, with over 100 such ADCs now in clinical trials for various malignancies including gastrointestinal tumors.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07481357 |
A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma |
RECRUITING | PHASE1 |
| NCT07477444 |
Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07318051 |
Sample Collection for Ongoing Research and Product Evaluation Study |
RECRUITING | |
| NCT06978062 |
Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment |
NOT_YET_RECRUITING | PHASE1 |
| NCT06906887 |
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer |
RECRUITING | PHASE2 |
| NCT06695845 |
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors |
RECRUITING | PHASE2 |
| NCT06497569 |
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer |
RECRUITING | NA |
| NCT06468280 |
Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer |
RECRUITING | PHASE2 |
| NCT06422403 |
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers |
RECRUITING | PHASE2 |
| NCT06410534 |
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer |
WITHDRAWN | PHASE2 |
